Please use this identifier to cite or link to this item:
|Title:||Systematic review of long-term chemotherapy-induced peripheral neuropathy (CIPN) following adjuvant oxaliplatin for colorectal cancer||Authors:||Teng, Christina ;Cohen, J.;Egger, S.;Blinman, P.L.||Affliation:||Central Coast Local Health District
|Issue Date:||Jan-2022||Source:||30(1):33-47||Journal title:||Supportive Care in Cancer||Department:||Central Coast Cancer Centre||Abstract:||PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) is the most common dose-limiting side effect of oxaliplatin. It often persists and can adversely affect quality of life of colorectal cancer (CRC) survivors. This systematic review explored the proportions of patients with persistent CIPN and the reporting methods used. METHODS: MEDLINE, EMBASE, Web of Science and CINAHL were searched up to March 2021 for publications reporting CIPN outcomes following adjuvant oxaliplatin-containing chemotherapy at prespecified timepoints in participants with CRC. Secondary outcomes assessed the tools used to measure CIPN. Two authors reviewed full text publications for eligibility, data extraction and appraisal. Meta-analysis was performed where Common Terminology Criteria for Adverse Events (any grade) was reported at the most frequent timepoints. RESULTS: From 7895 citations identified, 27 studies met the eligibility criteria: six were randomised control trials, and 21 were non-randomised studies. Pooled prevalence of CIPN at 6, 12, 24 and 36 months after chemotherapy were 58%, 45%, 32% and 24% respectively. The average prevalence of CIPN decreased by 26% per year after chemotherapy (pooled RR = 0.74; 95% CI 0.72-0.75). Across all studies, ten separate tools were used as the primary measure of CIPN. Quality appraisal identified open-label design and inadequate reporting of participants lost to follow-up as the main methodological limitations. CONCLUSION: Our summary of reported rates of persistent CIPN indicates substantial long-term toxicity affecting CRC survivors, and will help clinicians estimate CIPN risk and its change over time. The heterogeneity of CIPN measures identified in the review highlights the need for a standardised CIPN assessment.||URI:||https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/2073||DOI:||10.1007/s00520-021-06502-4||Pubmed:||https://pubmed.ncbi.nlm.nih.gov/34410459/||ISSN:||0941-4355||Publicaton type:||Journal Article||Keywords:||Cancer||Study or Trial:||Reviews/Systematic Reviews|
|Appears in Collections:||Oncology / Cancer|
Show full item record
checked on Feb 6, 2023
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.